Befejeződött1. fázis
Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)
Key facts
- Where
- Lille, Paris és Poitiers, FranciaországSee the 3 sites
- Phase
- 1. fázis
Where in Franciaország
- Centre Oscar LambretLille, FranciaországNo longer taking part
- Assistance Publique Hopitaux de ParisParis, FranciaországNo longer taking part
- Centre Hospitalier Universitaire de PoitiersPoitiers, FranciaországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Merck Sharp & Dohme LLC
- Trial code
- EU 2023-509542-35-00
- Record updated
- 2025. augusztus 25.